Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) and Its Plan for a Pivotal Phase III Study

Sorrento Therapeutics, Inc. has announced positive results from a phase IIa study of Abivertinib for the treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) in China. Abivertinib is a novel Bruton's tyrosine kinase (BTK) inhibitor that targets BTK irreversibly. The study included 27 R/R MZL patients treated with Abivertinib, and the overall response rate (ORR) was 59.3%, with 3 pat..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 6.
  • textsms

Harbour BioMed Announces Biologics License Application Acceptance of Batoclimab for Treatment of Generalized Myasthenia Gravis by NMPA

Harbour BioMed, a global biopharmaceutical company, has announced that the National Medical Products Administration (NMPA) of China has accepted its Biologics License Application (BLA) for batoclimab in the treatment of generalized myasthenia gravis (gMG). This marks the first BLA accepted by NMPA since Harbour BioMed's establishment. Batoclimab is an innovative therapy targeting anti-FcRn treat..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 2.
  • textsms